These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 31721468)

  • 1. The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib.
    Yang Y; Xu H; Yang G; Yang L; Li J; Wang Y
    Asia Pac J Clin Oncol; 2020 Feb; 16(1):63-69. PubMed ID: 31721468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer.
    Ock CY; Yoo SH; Keam B; Kim M; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS
    Korean J Intern Med; 2019 Sep; 34(5):1116-1124. PubMed ID: 29950554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance.
    Xu H; Yang G; Yang L; Yang Y; Ma D; Li J; Hao X; Xing P; Wang Y
    Thorac Cancer; 2019 May; 10(5):1096-1102. PubMed ID: 30920172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
    Nakagawa K; Hida T; Nokihara H; Morise M; Azuma K; Kim YH; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Kumagai T; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Koyama R; Mitsudomi T; Yamamoto N; Asakawa T; Hayashi M; Hasegawa W; Tamura T
    Lung Cancer; 2020 Jan; 139():195-199. PubMed ID: 31812890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China.
    Xing P; Wang S; Wang Q; Ma D; Hao X; Wang M; Wang Y; Shan L; Xin T; Liang L; Liang H; Du Y; Zhang Z; Li J
    Target Oncol; 2019 Jun; 14(3):325-333. PubMed ID: 31025247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review.
    Zhang B; Zhang Y; Xu J; Zhang X; Chu T; Wang S; Qian J; Qiao R; Lu J; Zhang L; Han B
    Target Oncol; 2018 Oct; 13(5):631-639. PubMed ID: 30218431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy.
    Delikgoz Soykut E; Kemal Y; Karacin C; Karaoglanoglu O; Kurt M; Aytac Arslan S
    J Med Imaging Radiat Oncol; 2022 Feb; 66(1):146-157. PubMed ID: 34632714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer.
    Cannon NA; Meyer J; Iyengar P; Ahn C; Westover KD; Choy H; Timmerman R
    J Thorac Oncol; 2015 Feb; 10(2):280-5. PubMed ID: 25299234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis?
    Unal D; Eroglu C; Kurtul N; Oguz A; Tasdemir A
    Asian Pac J Cancer Prev; 2013; 14(9):5237-42. PubMed ID: 24175807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
    Su Y; Long X; Song Y; Chen P; Li S; Yang H; Wu P; Wang Y; Bing Z; Cao Z; Cao L; Wu Y; Zhang Z; Liu J; Li B; Xiang J; Ma K; Zhang T; Zhang L; Mao X; Liu H; Xing P; Liang N
    Target Oncol; 2019 Apr; 14(2):159-168. PubMed ID: 30895431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With Immunotherapy.
    Prelaj A; Rebuzzi SE; Pizzutilo P; Bilancia M; Montrone M; Pesola F; Longo V; Del Bene G; Lapadula V; Cassano F; Petrillo P; Bafunno D; Varesano N; Lamorgese V; Mastrandrea A; Ricci D; Catino A; Galetta D
    Clin Lung Cancer; 2020 Jul; 21(4):365-377.e5. PubMed ID: 32245624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Yılmaz U; Ozdemir O; Batum O; Ermin S
    Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic.
    Miloš P; Jana S; Vítězslav K; Monika Š; Leona K; Jaromír R; Renata C; Markéta Č; Andrea B; Juraj K; Michal H; Milada Z; Marek K; Helena Č; Martin S
    Klin Onkol; 2018; 31(3):207-212. PubMed ID: 30441974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
    Camidge DR; Kim HR; Ahn MJ; Yang JC; Han JY; Lee JS; Hochmair MJ; Li JY; Chang GC; Lee KH; Gridelli C; Delmonte A; Garcia Campelo R; Kim DW; Bearz A; Griesinger F; Morabito A; Felip E; Califano R; Ghosh S; Spira A; Gettinger SN; Tiseo M; Gupta N; Haney J; Kerstein D; Popat S
    N Engl J Med; 2018 Nov; 379(21):2027-2039. PubMed ID: 30280657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of preoperative NLR, dNLR, PLR and CRP in surgical renal cell carcinoma patients.
    Hu H; Yao X; Xie X; Wu X; Zheng C; Xia W; Ma S
    World J Urol; 2017 Feb; 35(2):261-270. PubMed ID: 27255479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors.
    Liu N; Mao J; Tao P; Chi H; Jia W; Dong C
    Medicine (Baltimore); 2022 Jan; 101(3):e28617. PubMed ID: 35060536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.
    Zhang Y; Feng YC; Zhu HG; Xiong TC; Hou YS; Song J; Jiang W; Zhu CJ
    Medicine (Baltimore); 2018 Jul; 97(30):e11648. PubMed ID: 30045314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
    Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
    Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.